A scoping review highlights biomarkers and imaging techniques linked to musculoskeletal symptoms in breast cancer patients, suggesting future research directions.
Key Points
This review aims to summarize existing evidence on biologic and imaging markers associated with musculoskeletal symptoms related to aromatase inhibitors in breast cancer patients.
Conducted a scoping review examining original studies published from 2010 to 2025
Utilized databases including PubMed, EMBASE, COCHRANE, JAMA, and Medline
Included studies reporting biomarkers, inflammatory markers, and imaging techniques related to aromatase inhibitors
Thirteen studies met inclusion criteria primarily involving postmenopausal women aged 50-67 with early-stage hormone receptor-positive breast cancer
Identified biomarkers included CRP, IL6, estradiol, and genetic polymorphisms
Associated findings included elevated inflammatory cytokines and lower estradiol levels with AIMSS, and some imaging techniques showed promise for detecting tendon stiffness